Press release
Metastatic HER2+ve Breast Cancer Market on Track for Major Expansion by 2034, According to DelveInsight and Future Predictions Across APAC Region | Byondis, Roche, Ambrx, Zymeworks, Jazz Pharma
DelveInsight's "Metastatic HER2+ve Breast Cancer Patient Pool Analysis, Market Size and Market Forecast APAC - 2034 report offers an in-depth understanding of the Metastatic HER2+ve Breast Cancer, historical and forecasted epidemiology as well as the Metastatic HER2+ve Breast Cancer market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).
To Know in detail about the Metastatic HER2+ve Breast Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Metastatic HER2+ve Breast Cancer Market Forecast [https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Metastatic HER2+ve Breast Cancer Market Report:
*
The APAC Metastatic HER2+ve Breast Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In April 2025, Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have received European Union (EU) approval for ENHERTU Registered (trastuzumab deruxtecan) as a standalone treatment for adults with unresectable or metastatic breast cancer that is hormone receptor (HR) positive and either HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining). The approval applies to patients who have previously undergone at least one endocrine therapy for metastatic disease and are no longer considered candidates for further endocrine treatment.
*
Key Metastatic HER2+ve Breast Cancer Companies: Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, and others
*
Key Metastatic HER2+ve Breast Cancer Therapies: YD985 (trastuzumab duocarmazine), Giredestrant, ARX788, Zanidatamab, IBRANCE (palbociclib), and others
*
The Metastatic HER2+ve Breast Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Metastatic HER2+ve Breast Cancer pipeline products will significantly revolutionize the Metastatic HER2+ve Breast Cancer market dynamics.
Metastatic HER2+ve Breast Cancer Overview
Metastatic HER2-positive breast cancer refers to a specific subtype of breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body, and it is characterized by the presence of human epidermal growth factor receptor 2 (HER2) protein overexpression or gene amplification.
Get a Free sample for the Metastatic HER2+ve Breast Cancer Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market-size-and-forecast [https://www.delveinsight.com/report-store/metastatic-her2-positive-breast-cancer-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Metastatic HER2+ve Breast Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2020-2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Metastatic HER2+ve Breast Cancer Epidemiology Segmentation:
The Metastatic HER2+ve Breast Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the APAC region is segmented into:
*
Total Prevalence of Metastatic HER2+ve Breast Cancer
*
Prevalent Cases of Metastatic HER2+ve Breast Cancer by severity
*
Gender-specific Prevalence of Metastatic HER2+ve Breast Cancer
*
Diagnosed Cases of Episodic and Chronic Metastatic HER2+ve Breast Cancer
Download the report to understand which factors are driving Metastatic HER2+ve Breast Cancer epidemiology trends @ Metastatic HER2+ve Breast Cancer Epidemiology Forecast [https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Metastatic HER2+ve Breast Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic HER2+ve Breast Cancer market or expected to get launched during the study period. The analysis covers Metastatic HER2+ve Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Metastatic HER2+ve Breast Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Metastatic HER2+ve Breast Cancer Therapies and Key Companies
*
SYD985 (trastuzumab duocarmazine): Byondis
*
Giredestrant: Roche
*
ARX788: Ambrx
*
Zanidatamab: Zymeworks/Jazz Pharmaceuticals
*
IBRANCE (palbociclib): Pfizer
Discover more about therapies set to grab major Metastatic HER2+ve Breast Cancer market share @ Metastatic HER2+ve Breast Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of the Metastatic HER2+ve Breast Cancer Market Report
*
Study Period: 2020-2034
*
Coverage: APAC (India, China, South Korea, Taiwan, and Australia)
*
Key Metastatic HER2+ve Breast Cancer Companies: Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, and others
*
Key Metastatic HER2+ve Breast Cancer Therapies: YD985 (trastuzumab duocarmazine), Giredestrant, ARX788, Zanidatamab, IBRANCE (palbociclib), and others
*
Metastatic HER2+ve Breast Cancer Therapeutic Assessment: Metastatic HER2+ve Breast Cancer current marketed and Metastatic HER2+ve Breast Cancer emerging therapies
*
Metastatic HER2+ve Breast Cancer Market Dynamics: Metastatic HER2+ve Breast Cancer market drivers and Metastatic HER2+ve Breast Cancer market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Metastatic HER2+ve Breast Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic HER2+ve Breast Cancer Market Access and Reimbursement
To know more about Metastatic HER2+ve Breast Cancer companies working in the treatment market, visit @ Metastatic HER2+ve Breast Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/metastatic-her2-positive-breast-cancer-market-size-and-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Metastatic HER2+ve Breast Cancer Market Report Introduction
2. Executive Summary for Metastatic HER2+ve Breast Cancer
3. SWOT analysis of Metastatic HER2+ve Breast Cancer
4. Metastatic HER2+ve Breast Cancer Patient Share (%) Overview at a Glance
5. Metastatic HER2+ve Breast Cancer Market Overview at a Glance
6. Metastatic HER2+ve Breast Cancer Disease Background and Overview
7. Metastatic HER2+ve Breast Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Metastatic HER2+ve Breast Cancer
9. Metastatic HER2+ve Breast Cancer Current Treatment and Medical Practices
10. Metastatic HER2+ve Breast Cancer Unmet Needs
11. Metastatic HER2+ve Breast Cancer Emerging Therapies
12. Metastatic HER2+ve Breast Cancer Market Outlook
13. Country-Wise Metastatic HER2+ve Breast Cancer Market Analysis (2020-2034)
14. Metastatic HER2+ve Breast Cancer Market Access and Reimbursement of Therapies
15. Metastatic HER2+ve Breast Cancer Market Drivers
16. Metastatic HER2+ve Breast Cancer Market Barriers
17. Metastatic HER2+ve Breast Cancer Appendix
18. Metastatic HER2+ve Breast Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-her2ve-breast-cancer-market-on-track-for-major-expansion-by-2034-according-to-delveinsight-and-future-predictions-across-apac-region-byondis-roche-ambrx-zymeworks-jazz-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic HER2+ve Breast Cancer Market on Track for Major Expansion by 2034, According to DelveInsight and Future Predictions Across APAC Region | Byondis, Roche, Ambrx, Zymeworks, Jazz Pharma here
News-ID: 4001978 • Views: …
More Releases from ABNewswire
Blue Sky Scrubs Celebrates National Nurses Week - Giving Back
Blue Sky Scrubs Honors Nurses Week with 20% Off All Products and a Commitment to Giving Back
Image: https://www.abnewswire.com/upload/2025/05/0d32b3df83dece900e9c46088ed794fb.jpg
Austin, TX - May 6, 2025 - In celebration of National Nurses Week, Blue Sky Scrubs, the Austin-based designer medical apparel brand, is proud to announce a special promotion honoring nurses and healthcare professionals everywhere. From May 6-12, all customers will receive 20% off all Blue Sky Scrubs products-no exclusions, no minimum purchase…
HER2-Negative Breast Cancer Market to Reach New Heights in Growth by 2032, Delve …
The Key HER2-Negative Breast Cancer Companies in the market include - Genentech, Inc., AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene, Eisai Inc., Novartis Pharmaceuticals, Adagene Inc, Jiangsu HengRui Medicine Co., Ltd, Pfizer, Novartis, CytomX Therapeutics, Tyme, Inc, Puma Biotechnology, Inc., G1 Therapeutics, Inc., Context Therapeutics Inc., and others.
DelveInsight's "HER2-Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the HER2-Negative Breast Cancer, historical…
Leo Bottary's Peernovation Reveals How to Drive Higher, Healthier Team Performan …
In Peernovation: Forged by CEO Forums. Perfected for Teams (Second Edition), Leo Bottary unlocks strategies for building collaborative, high-performing teams that are built to thrive in today's fast-paced business world.
Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXeaie6pEUbS0_jlRXiX8McMwmtMMzCmGXeAntvm-7oHmeupvPIpcXJEG4NZ0EZMpiNhVP-nG4UZWO5JptYjSZnYvG9p6kNQK_zCqksHJKMJqK4xGSTsOJ8VkSb3KGTFIQo?key=SClhx8vPv2h3SlrObiT6lhtq
Leo Bottary is a renowned author, keynote speaker, and the founder and managing partner of Peernovation, LLC, dedicated to fostering high-performing teams and peer collaboration. His groundbreaking work explores how leveraging peer relationships drives personal and organizational success. Leo's books…
Oral Mucositis Market Anticipated to Expand Rapidly During 2024-2034, Says Delve …
The Key Oral Mucositis Companies in the market include - Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix, Monopar Therapeutics, MitoImmune Therapeutics, and others.
The Oral Mucositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Oral Mucositis pipeline products will significantly revolutionize the Oral Mucositis market dynamics.
DelveInsight's "Oral Mucositis Market Insights, Epidemiology, and Market Forecast-2034 report…
More Releases for HER2
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
HER2 Antibodies Market Expand with Significant CAGR During 2018-2025
Global HER2 Antibodies Market: Overview
Among all the chronic diseases worldwide cancer is considered to be the most prevalent disease. Approximately 1,685,210 new cancer cases were diagnosed and about 595,690 cancer deaths in the US in year 2016. Whereas around 2,600 men and 246,660 that is about 29% women were diagnosed with breast cancer in year 2016. HER2 breast cancer is one of the aggressive type of breast cancer, caused due…
HER2 Antibodies Market to approach US$ 21,669.1 mn by 2025
A recent market intelligence study by Transparency Market Research (TMR) suggests that the global HER2 antibodies market offers lucrative opportunities as the awareness regarding breast cancer and personalized medicines spreads. Consequently, the competitive landscape of the HER2 antibodies market is already quite intense with the presence of a large number of players, both global and regional. The report identifies Pfizer, Inc., Novartis AG, Genentech Inc. by F. Hoffmann-La Roche Ltd.,…
HER2 Antibodies Market Key Trends and Forecast Research Report 2025
As per the projections of the TMR report, the demand in the global HER2 antibodies market will multiply at an impressive CAGR of 8.6% during the forecast period of 2017 to 2025, achieving an estimated global valuation of US$21,669.1 mn by the end of 2025, substantially up from its evaluated worth of US$10,087.8 mn in 2016. In the near future, new drug development is expected to be based on adjuvant…
HER2 Antibodies Market Key Trends and Forecast Research Report 2025
As per the projections of the TMR report, the demand in the global HER2 antibodies market will multiply at an impressive CAGR of 8.6% during the forecast period of 2017 to 2025, achieving an estimated global valuation of US$21,669.1 mn by the end of 2025, substantially up from its evaluated worth of US$10,087.8 mn in 2016. In the near future, new drug development is expected to be based on adjuvant…
Her2 Antibodies Market: Industry Overview and Key Factors
Global Her2 Antibodies Market: Overview
Human epidermal growth factor receptor 2 (Her2) refers to an oncogene whose over-expression or amplification is commonly associated with the development of an aggressive type of breast cancer. Patients having the over-expression of Her2 receptors are diagnosed with the help of tests such as Fluorescent In-Situ Hybridization (FISH) and Immunohistochemistry (IHC).
The American Cancer Society states that around 15-30% of breast cancer cases over-express the Her2…
